三家上市公司同日停牌筹划“易主”两药企陷业绩泥潭

Core Viewpoint - Three listed companies, Duori Pharmaceutical, Asia-Pacific Pharmaceutical, and Zhonghuan Environmental Protection, announced on the same day that they are planning changes in control, which may lead to changes in their controlling shareholders and actual controllers [1] Group 1: Duori Pharmaceutical - Duori Pharmaceutical's major shareholder, Tibet Jiakang Times Technology Development Co., is planning a change in control, which may lead to a change in the company's controlling shareholder and actual controller [2] - The company has experienced continuous revenue decline from 2022 to 2024, which may be a reason for the planned change in control [2] - Duori Pharmaceutical's revenue for the first half of 2025 was 107 million yuan, a year-on-year decline of 29.13%, with a net loss of 42.5 million yuan, compared to a loss of 3.27 million yuan in the same period last year [3] Group 2: Asia-Pacific Pharmaceutical - Asia-Pacific Pharmaceutical's major shareholder, Ningbo Fubang Holdings Group, is also planning a change in control, with specific transaction plans and agreements still under discussion [4] - The company has faced continuous revenue decline, with a net profit of -48.86 million yuan for the first half of 2025, a year-on-year decrease of 524.31% [5] - Asia-Pacific Pharmaceutical's revenue for the first half of 2025 was 152 million yuan, a year-on-year decrease of 31.48%, attributed to centralized procurement and intensified market competition [5]